RAIN Stock Price, Rain Therapeutics Inc. Quote, Chart

Market Summary

USD0.04+0.01

Market Closed

33.33%

RAIN Stock Price

View Fullscreen

RAIN RSI Chart

RAIN Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.02

EV/EBITDA

0.48

Price/Free Cashflow

-0.02

MarketCap/EBT

-0.01

RAIN Price/Earnings (Trailing)

RAIN Profitability

Return on Equity

-107.02%

Return on Assets

-88.06%

Free Cashflow Yield

-6.0K%

RAIN Fundamentals

RAIN Earnings

Earnings (TTM)

-72.3M

Earnings Growth (Yr)

61.01%

Earnings Growth (Qtr)

68.12%

Breaking Down RAIN Revenue

Last 30 days

200%

Last 90 days

200%

Trailing 12 Months

50%

How does RAIN drawdown profile look like?

RAIN Financial Health

Current Ratio

5.58

RAIN Investor Care

Shares Dilution (1Y)

36.93%

Diluted EPS (TTM)

-2.07

Tracking the Latest Insider Buys and Sells of Rain Therapeutics Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 26, 2024	davis aaron i.	sold	-	-	-79,726	-
Jan 26, 2024	radovich peter	sold	-	-	-8,796	-
Jan 26, 2024	doebele robert	sold	-	-	-476,827	see remarks
Jan 26, 2024	tang kevin c	sold	-	-	-3,850,510	-
Jan 26, 2024	vellanki avanish	sold	-	-	-2,550,910	chairman and ceo
Jan 26, 2024	berger franklin m	sold	-	-	-1,005,210	-
Jan 25, 2024	bvf partners l p/il	sold	-	-	-3,288,190	-
Jan 25, 2024	bvf partners l p/il	sold	-	-	-5,288,620	-
Dec 18, 2023	tang kevin c	sold	-48,559	1.21	-40,132	-
Dec 15, 2023	tang kevin c	sold	-131,322	1.2	-109,435	-

Which funds bought or sold RAIN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 12, 2024	PVG ASSET MANAGEMENT CORP	sold off	-100	-40,952	-	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-3.35	269,035	1,046,950	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-24,504	-	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	3.57	3,232	10,541	-%
Feb 26, 2024	Virtu Financial LLC	new	-	40,000	40,000	-%
Feb 15, 2024	GTS SECURITIES LLC	new	-	60,020	60,020	-%
Feb 15, 2024	HORIZON KINETICS ASSET MANAGEMENT LLC	reduced	-4.03	7,245	28,790	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	54,254	54,254	-%
Feb 15, 2024	BARCLAYS PLC	added	883	27,000	29,000	-%
Feb 15, 2024	Legal & General Group Plc	unchanged	-	646	2,290	-%

Are Funds Buying or Selling RAIN?

Are funds buying RAIN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RAIN

No. of Funds

Unveiling Rain Therapeutics Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	samsara biocapital, l.p.	0%	0	SC 13G/A
Feb 14, 2024	perceptive advisors llc	0.0%	0	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	0%	0	SC 13G/A
Feb 02, 2024	tang capital partners lp	0%	0	SC 13D/A
Jan 29, 2024	biotechnology value fund l p	-	0	SC 13D/A
Dec 20, 2023	vellanki avanish	7.0%	2,550,910	SC 13D/A
Dec 18, 2023	biotechnology value fund l p	6.3%	1,734,960	SC 13D/A
Dec 18, 2023	boxer capital, llc	9.9%	2,933,152	SC 13D/A
Nov 24, 2023	bml investment partners, l.p.	4.8%	1,315,025	SC 13G
Oct 13, 2023	tang capital partners lp	14.6%	4,024,486	SC 13D/A

Recent SEC filings of Rain Therapeutics Inc.

View All Filings

Date Filed	Form Type	Document
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 07, 2024	SC 13G/A	Major Ownership Report
Feb 05, 2024	15-12G	15-12G
Feb 02, 2024	4	Insider Trading
Feb 02, 2024	SC 13D/A	13D - Major Acquisition
Jan 30, 2024	EFFECT	EFFECT
Jan 29, 2024	4	Insider Trading
Jan 29, 2024	SC 13D/A	13D - Major Acquisition
Jan 26, 2024	4	Insider Trading

Peers (Alternatives to Rain Therapeutics Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.2B	6.8B	-1.24%	-34.47%	-8.53	5.87	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.7B	1.8B	0.05%	-28.38%	-42.48	10.23	76.23%	61.08%
BMRN	17.4B	2.4B	8.82%	-6.19%	103.82	7.19	15.42%	18.43%
INCY	12.1B	3.7B	-8.57%	-28.49%	20.24	3.27	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.73%	-34.59%	-11.81	15.74	425.83%	18.94%
BBIO	4.7B	-	-4.69%	71.46%	-7.23	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-0.99%	6.40%	-13.71	12.12	440.80%	-27.84%
ARWR	3.1B	240.7M	-13.54%	-18.95%	-10.32	12.72	-1.03%	-92.09%
ACAD	2.8B	726.4M	-12.42%	-7.51%	-46.06	3.89	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-15.36%	25.1	4.5	85.90%	-14.05%
NVAX	599.0M	983.7M	-18.48%	-55.04%	-1.1	0.61	-50.36%	17.16%
CRBP	428.3M	881.7K	-13.30%	407.71%	-9.6	466.16	-77.61%	-5.33%
INO	257.8M	4.9M	-1.96%	-2.22%	-1.91	52.97	-54.97%	51.72%
IBIO	7.2M	2.1M	77.59%	88.99%	-0.26	2.14	-13.45%	66.37%

Rain Therapeutics Inc. News

Latest updates

Rain Therapeutics Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-10.5%	82.00	92.00	114	135	95.00	111	128	147	159	175	56.00	61.00
Current Assets	-11.2%	81.00	91.00	113	134	94.00	110	127	146	157	173	54.00	60.00
Cash Equivalents	-6.9%	37.00	40.00	44.00	62.00	40.00	43.00	22.00	25.00	13.00	118	53.00	59.00
Net PPE	74.0%	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-21.1%	15.00	18.00	20.00	22.00	13.00	12.00	13.00	17.00	11.00	10.00	6.00	4.00
Current Liabilities	-21.0%	14.00	18.00	19.00	22.00	13.00	12.00	13.00	16.00	11.00	9.00	5.00	3.00
Shareholder's Equity	-7.9%	68.00	73.00	95.00	113	81.00	98.00	114	131	147	165	-	-
Retained Earnings	-3.4%	-215	-208	-186	-165	-143	-124	-107	-89.96	-71.98	-53.55	-45.37	-38.57
Additional Paid-In Capital	0.4%	283	282	281	279	225	224	222	221	219	218	1.00	1.00
Shares Outstanding	0%	36.00	36.00	36.00	36.00	27.00	27.00	27.00	26.00	26.00	21.00	1.00	1.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	70.4%	-6,999	-23,624	-21,839	-13,294	-15,363	-17,432	-17,110	-9,759	-11,954	-10,884	-4,866	-4,456	-2,351	-1,934	-2,490
Share Based Compensation	46.7%	1,228	837	1,568	1,264	932	1,417	1,242	1,272	862	793	165	269	201	196	199
Cashflow From Investing	-78.4%	4,235	19,588	3,518	-17,192	11,626	39,324	13,436	21,245	-92,801	-46,650	-29.00	-	-	-	-
Cashflow From Financing	-100.0%	-	12.00	466	52,607	162	12.00	399	36.00	-	122,437	-858	-	-	-	-

RAIN Income Statement

2023-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 3,965	$ 14,510	$ 35,622	$ 42,322
General and administrative	4,113	3,901	14,593	11,257
Restructuring charges			2,837
Total operating expenses	8,078	18,411	53,052	53,579
Loss from operations	(8,078)	(18,411)	(53,052)	(53,579)
Other income:
Interest income	1,044	370	3,470	533
Total other income	1,044	370	3,470	533
Net loss	$ (7,034)	$ (18,041)	$ (49,582)	$ (53,046)
Net loss per share, basic	$ (0.19)	$ (0.68)	$ (1.36)	$ (2.00)
Net loss per share, diluted	$ (0.19)	$ (0.68)	$ (1.36)	$ (2.00)
Weighted-average shares used to compute net loss per share, basic	36,375,671	26,564,615	36,359,744	26,535,474
Weighted-average shares used to compute net loss per share, diluted	36,375,671	26,564,615	36,359,744	26,535,474
Other comprehensive loss:
Unrealized gain (loss) on short-term investments	$ 36	$ 71	$ 102	$ (213)
Comprehensive loss	$ (6,998)	$ (17,970)	$ (49,480)	$ (53,259)

RAIN Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 37,312	$ 61,955
Short-term investments	40,008	68,499
Prepaid and other current assets	3,496	3,174
Total current assets	80,816	133,628
Property and equipment, net	628	93
Operating lease right-of-use asset	436	258
Other assets	180	1,201
Total assets	82,060	135,180
Current liabilities:
Accounts payable	8,973	7,146
Accrued research and development	2,858	8,232
Other accrued liabilities	2,190	6,424
Operating lease liability, current portion	456	164
Total current liabilities	14,477	21,966
Operating lease liability, net of current portion		113
Other long-term liabilities	64	65
Total liabilities	14,541	22,144
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 250,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 36,375,671 shares (comprised of 27,579,947 shares of common stock and 8,795,724 shares of non-voting common stock) and 36,290,292 shares (comprised of 25,947,572 shares of common stock and 10,342,720 shares of non-voting common stock) issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	37	37
Additional paid-in capital	282,816	278,853
Accumulated other comprehensive loss	(64)	(166)
Accumulated deficit	(215,270)	(165,688)
Total stockholders' equity	67,519	113,036
Total liabilities and stockholders' equity	$ 82,060	$ 135,180

About Rain Therapeutics Inc.

Rain Oncology Inc., a late-stage precision oncology company, engages in developing therapies that target oncogenic drivers to genetically select patients in the United States. The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.

CEO	Mr. Avanish Vellanki M.B.A.
WEBSITE	rainoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	63

Rain Therapeutics Inc. Frequently Asked Questions

What is the ticker symbol for Rain Therapeutics Inc.? What does RAIN stand for in stocks?

RAIN is the stock ticker symbol of Rain Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rain Therapeutics Inc. (RAIN)?

As of Thu Apr 11 2024, market cap of Rain Therapeutics Inc. is 1.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RAIN stock?

You can check RAIN's fair value in chart for subscribers.

What is the fair value of RAIN stock?

You can check RAIN's fair value in chart for subscribers. The fair value of Rain Therapeutics Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rain Therapeutics Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RAIN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rain Therapeutics Inc. a good stock to buy?

The fair value guage provides a quick view whether RAIN is over valued or under valued. Whether Rain Therapeutics Inc. is cheap or expensive depends on the assumptions which impact Rain Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RAIN.